Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases
Recruitment status was Recruiting
RATIONALE: Giving chemotherapy before a donor peripheral stem cell transplant or bone marrow transplant using stem cells from a brother or sister that closely match the patient's stem cells, helps stop the growth of cancer or abnormal cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer or abnormal cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving colony-stimulating factors, such as G-CSF, to the donor helps the stem cells move from the bone marrow to the blood so they can be collected and stored. Giving methotrexate and cyclosporine before and after transplant may stop this from happening. It is not yet known whether a donor peripheral stem cell transplant is more effective than a donor bone marrow transplant in treating hematologic cancers or other diseases.
PURPOSE: This randomized phase III trial is studying filgrastim-mobilized sibling donor peripheral stem cell transplant to see how well it works compared with sibling donor bone marrow transplant in treating patients with hematologic cancers or other diseases.
Chronic Myeloproliferative Disorders
Graft Versus Host Disease
Procedure: allogeneic bone marrow transplantation
Procedure: peripheral blood stem cell transplantation
|Study Design:||Allocation: Randomized
Primary Purpose: Treatment
|Official Title:||A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies|
- Time to treatment failure (extensive chronic graft-versus-host disease [GVHD], relapse, death) [ Designated as safety issue: No ]
- Time to neutrophil recovery [ Designated as safety issue: No ]
- Primary graft failure [ Designated as safety issue: No ]
- Overall survival [ Designated as safety issue: No ]
- Quality of life [ Designated as safety issue: No ]
- Time to acute GVHD [ Designated as safety issue: No ]
- Time to chronic GVHD [ Designated as safety issue: No ]
- Chronic GVHD details [ Designated as safety issue: No ]
- Cost [ Designated as safety issue: No ]
- Detailed donor and patient self-reported outcomes [ Designated as safety issue: No ]
|Study Start Date:||March 2007|
Active Comparator: Arm I
Patients undergo filgrastim (G-CSF)-mobilized sibling donor peripheral blood SCT on day 0.
Given on day 0.Procedure: peripheral blood stem cell transplantation
Given on day 0
Experimental: Arm II
Patients undergo G-CSF-mobilized sibling donor bone marrow transplantation on day 0.
Given on day 0.Procedure: allogeneic bone marrow transplantation
Given on day 0
- Compare the time to treatment failure in patients with hematologic malignancies or other diseases treated with filgrastim (G-CSF)-mobilized matched-sibling donor peripheral blood stem cell transplantation vs G-CSF-stimulated matched-sibling donor bone marrow transplantation.
- Compare the hematological recovery and overall survival of patients treated with these regimens.
- Compare the quality of life, in terms of extensive graft-versus-host disease (GVHD), in patients treated with these regimens.
- Compare the economic impact associated with these treatment regimens.
- Compare the incidence and severity of acute GVHD in patients treated with these regimens.
- Compare organ involvement, symptomatology, and functional impact of chronic GVHD in patients treated with these regimens.
- Compare disease-free survival of patients treated with these regimens.
- Compare donor quality of life.
- Compare cost analysis, from a societal perspective, of these treatment regimens.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to treatment center, disease (chronic myelogenous leukemia vs acute myeloid leukemia vs myelodysplastic syndromes vs other hematologic malignancy), disease stage (early disease vs late disease), and conditioning regimen (busulfan and cyclophosphamide vs cyclophosphamide and total body irradiation vs other).
- Myeloablative conditioning regimen: Patients receive a myeloablative conditioning regimen that has been approved by the clinical chair.
Stem cell transplantation (SCT): Patients are randomized to 1 of 2 SCT arms.
- Arm I: Patients undergo sibling donor filgrastim (G-CSF)-mobilized peripheral blood SCT on day 0.
- Arm II: Patients undergo sibling donor G-CSF- mobilized bone marrow transplantation on day 0.
- Graft-verus-host disease (GVHD) treatment: Patients receive methotrexate IV on days 1, 3, 6, and 11 and cyclosporine IV (or orally) every 12 hours beginning on day -2 and continuing until day 100.
Quality of life is assessed at baseline and at 1 and 3 years post-transplantation.
After completion of study therapy, patients are followed periodically for at least 4 years.
PROJECTED ACCRUAL: A total of 230 patients will be accrued for this study.
|United States, Washington|
|Fred Hutchinson Cancer Research Center||Recruiting|
|Seattle, Washington, United States, 98109-1024|
|Contact: Stephanie J. Lee, MD 206-667-5160|
|Australia, South Australia|
|Institute of Medical and Veterinary Science||Recruiting|
|Adelaide, South Australia, Australia, 5000|
|Contact: Ian D. Lewis, MD 61-8-8222-3421 firstname.lastname@example.org|
|Royal Melbourne Hospital||Recruiting|
|Parkville, Victoria, Australia, 3050|
|Contact: David Curtis, MD 61-3-9342-7386|
|Canada, British Columbia|
|Vancouver Hospital and Health Science Center||Recruiting|
|Vancouver, British Columbia, Canada, V5Z 4E3|
|Contact: Cynthia Toze, MD 604-875-4863|
|Winnipeg, Manitoba, Canada, R3E 0V9|
|Contact: Morel Rubinger, MD, FRCPC 204-787-3594 Morel.email@example.com|
|Canada, Nova Scotia|
|Cancer Care Nova Scotia||Recruiting|
|Halifax, Nova Scotia, Canada, B3H 2Y9|
|Contact: Stephen Couban, MD 902-473-7006 firstname.lastname@example.org|
|McMaster Children's Hospital at Hamilton Health Sciences||Recruiting|
|Hamilton, Ontario, Canada, L8N 3Z5|
|Contact: Irwin Walker, MD 905-521-2100|
|London Regional Cancer Program at London Health Sciences Centre||Recruiting|
|London, Ontario, Canada, N6A 465|
|Contact: Kang Howson-Jan, MD 519-685-5194 Kang.email@example.com|
|Ottawa Hospital Regional Cancer Centre - General Campus||Recruiting|
|Ottawa, Ontario, Canada, K1H 8L6|
|Contact: Lothar B. Huebsch, MD 613-737-8158 firstname.lastname@example.org|
|Princess Margaret Hospital||Recruiting|
|Toronto, Ontario, Canada, M5G 2M9|
|Contact: Jeffrey H. Lipton, MD, PhD 416-946-2266 email@example.com|
|Montreal, Quebec, Canada, H1T 2M4|
|Contact: Silvy Lachance, MD, FRCP 514-252-3404|
|Royal Victoria Hospital - Montreal||Recruiting|
|Montreal, Quebec, Canada, H3A 1A1|
|Contact: Ahmed Galal, MD 514-843-1558|
|Hopital de L'Enfant Jesus||Recruiting|
|Quebec City, Quebec, Canada, G1J 1Z4|
|Contact: Robert Delage, MD 418-649-5727 firstname.lastname@example.org|
|Centre Hospitalier Universitaire de Quebec||Recruiting|
|Quebec City, Quebec, Canada, G1R 2J6|
|Contact: Marc Lalancette, MD, FRCPC 418-691-5225 email@example.com|
|Auckland City Hospital||Recruiting|
|Auckland, New Zealand, 1|
|Contact: Richard Doocey, MD 64-9-307-4949 ext. 23306|
|King Faisal Specialist Hospital and Research Center||Recruiting|
|Riyadh, Saudi Arabia, 11211|
|Contact: Mahmoud D. Aljurf, MD, MPH 966-1-464-7272 firstname.lastname@example.org|
|Study Chair:||Stephen Couban, MD||Cancer Care Nova Scotia|
|Investigator:||Jeffrey H. Lipton, MD, PhD||Princess Margaret Hospital, Canada|